Company Legal Name
Latest Valuation
Founded Year
Headquarter
Antithesis operates a continuous reliability platform that autonomously discovers, reproduces, and tests software bugs within simulated environments, eliminating risks to production systems. Founded in 2018 and headquartered in Vienna, United States, the company addresses critical software reliability challenges by providing developers with comprehensive bug detection capabilities before deployment. Their platform differentiates itself through autonomous testing methodology that simulates real-world conditions while maintaining complete isolation from live systems. This approach enables organizations to identify and resolve software vulnerabilities proactively, reducing costly production failures and improving overall system reliability. Antithesis continues focusing on advancing automated software testing solutions for enterprise clients.
Revenue & Revenue Growth Share
Revenue
Revenue Growth
Available in most regions; subject to local regulations.
Open to non-accredited investors with KYC/AML compliance. U.S. investors must meet SEC requirements.
$10 per token, enabling fractionalized access to Pre-IPO shares.
Mandatory identity (KYC) and proof of funds checks.
Variable, applied to investment amounts.
Charged on realized profits.
Tokens may be locked for 6–12 months; resale depends on secondary market liquidity.
Prices reflect past funding rounds, not guaranteed future value.
Biotech depends on regulatory approvals; fintech faces evolving digital asset rules.
Blockchain or custodian issues could delay transfers or verification.
Changing laws may affect tradability or taxation.





